EMEA-000200-PIP01-08-M10 - paediatric investigation plan

Saxagliptin

Key facts

• Invented name:
  • Onglyza
  • Onglyza
• Active Substance:
  Saxagliptin
• Therapeutic area:
  Endocrinology-Gynaecology-Fertility-Metabolism
• Decision number:
  P/0478/2022
• PIP number:
  EMEA-000200-PIP01-08-M10
• Pharmaceutical form(s):
  Film-coated tablet
• Condition(s) / indication(s):
  Treatment of type II diabetes mellitus
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  AstraZeneca AB

  E-mail: [e-mail]; Tel. [phone]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  02/12/2022

Decision

P/0478/2022: EMA decision of 2 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for saxagliptin (Onglyza), (EMEA-000200-PIP01-08-M10)

AdoptedReference Number: EMA/899035/2022